Form 8-K · Current Report · Filed 2025-01-30
ResMed Inc. Reports Strong Q2 2025 Financial Results and Declares Dividend
ResMed Inc. announced its financial results for the quarter ended December 31, 2024, reporting a 10% year-over-year revenue growth to $1.28 billion and a 52% increase in income from operations to $417.2 million. The company also declared a quarterly cash dividend of $0.53 per share, payable on March 20, 2025, with a record date of February 13, 2025.
- Filer
- ResMed Inc. RMD · NYSE
- Filed
- Accession
- 0001193125-25-017218
- CIK
- 0000943819
- Signal
- Medium impactHealthcare
- Source
- Official filing on sec.gov ↗
Items reported
Results of Operations and Financial Condition
Other Events
Financial Statements and Exhibits
Market reaction
Close before filing
$252.86
Next session
-6.6%
Since filing
-16.6%
Latest close
$210.98
What happened, not what will happen — closing prices around the filing date.
Precedent
Previous filings from RMD reporting the same item, with the next session's move:
Exhibits (1)
About ResMed Inc.
ResMed Inc. is an innovative leader in the development and manufacturing of devices focused on improving the quality of sleep and respiratory health. Operating globally, ResMed specializes in producing advanced equipment for sleep apnea therapy, chronic obstructive pulmonary disease (COPD), and various respiratory conditions. The company's offerings include a range of cutting-edge products like continuous positive airway pressure (CPAP) devices, bilevel systems, and ventilators, designed to enhance patient comfort and compliance. ResMed is also at the forefront of integrating cloud-connected devices to support improved patient monitoring and telemedicine services. The healthcare industry, particularly the medical device sector, benefits significantly from ResMed's contributions, as the company aims to address the growing needs associated with sleep and respiratory conditions. By focusing on both personal and overarching health care solutions, ResMed plays a crucial role in enhancing patient quality of life, thereby solidifying its position as a key player in the global health and respiratory care markets.
Never miss another RMD filing
Profitelligence watches EDGAR around the clock and alerts you within seconds.